Vilin Bio Med Limited Incorporates Two Wholly Owned Subsidiaries in Pharmaceutical Sector
Vilin Bio Med Limited has confirmed it is incorporating two new wholly owned subsidiaries, Vilo Speciality Pharma Private Limited and Axia Pharma Private Limited. The Company has agreed to subscribe to the capital of these entities following the approval of their names by the Ministry of Corporate Affairs. Both companies are set up within the pharmaceutical industry.The incorporation of these new subsidiaries aims to expand Vilin Bio Med's presence across various pharmaceutical production, marketing, and distribution segments.
Details regarding the proposed subsidiary, Vilo Speciality Pharma Private Limited (VSPPL), have been disclosed. The company is being formed with a Proposed Authorized Capital of Rs.10,00,000, comprising 1,00,000 Equity Shares of Rs.10 each.
The objects for VSPPL cover the marketing and distribution of Oncology Pharmaceutical Products and related services. These objectives include:
- Marketing, Promotion, Branding, Distribution, Wholesale, Trading, Import, Export, Buying, and Selling of Oncology Pharmaceutical Products and Specialty Pharmaceutical Products.
- Providing Product Management, Sales Promotion, Medical Marketing, Advertising, Business Development, Market Research, and Consultancy in relation to Oncology Pharmaceutical, Bio-technology, and Healthcare products.
- Undertaking the Manufacture, Processing, Packaging, Labelling, Distribution, and Supply of Oncological and Healthcare Products through internal or third party facilities.
VSPPL is categorized under the Pharmaceutical Industry, and the Company intends to hold a 100% stake in the entity as it is proposed to be incorporated as a Wholly Owned Subsidiary.
Axia Pharma Private Limited established for General Pharmaceutical Needs
The second subsidiary, Axia Pharma Private Limited (APPL), also falls under the Pharmaceutical Industry and holds a Proposed Authorized Capital of Rs.10,00,000, consisting of 1,00,000 Equity Shares valued at Rs.10 each.The objectives for APPL are broad, focusing on marketing and supply across numerous pharmaceutical product categories. These include:
- Marketing, Promotion, Branding, Distribution, Wholesale, Trading, Import, Export, Buying, and Selling of Pharmaceutical Products, Medicines, Medicinal Substances, Active Pharmaceutical Ingredients (API), Anti-biotics, Endocrine Products, Vitamins, Opium Derivatives, Sulpha Drugs, Serums, Plasmas, Salicylic Acid and Salts and Esters, Glycosides, Vegetable Alkaloids, Chemically Pure Sugars, Generic Pharmaceutical Products, Healthcare Products, and Allied Preparations.
- Providing Product Management, Sales Promotion, Generic Pharmaceutical Marketing, Business Development, Advertising, Market Research, and Consultancy services related to Pharmaceutical, Bio-technology, and Healthcare products.
Like VSPPL, APPL is planned as a Wholly Owned Subsidiary with the Company intending to acquire 100% shareholding control upon incorporation.
VILINBIO Stock Price Movement
Vilin Bio Med Limited shares slipped today, closing at ₹44.25 after shedding 4.84% from the previous close. The stock finished its trading session with a recorded volume of 4,000 shares in post-market activity.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.